Dishman Carbogen [DCAL] vs Supriya Lifescience [SUPRIYA] Detailed Stock Comparison

Dishman Carbogen
NSE
Loading...

Supriya Lifescience
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Dishman Carbogen wins in 10 metrics, Supriya Lifescience wins in 9 metrics, with 0 ties. Dishman Carbogen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Dishman Carbogen | Supriya Lifescience | Better |
---|---|---|---|
P/E Ratio (TTM) | 1,253.10 | 29.41 | Supriya Lifescience |
Price-to-Book Ratio | 0.71 | 5.22 | Dishman Carbogen |
Debt-to-Equity Ratio | 40.97 | 0.54 | Supriya Lifescience |
PEG Ratio | 21.05 | -1.34 | Supriya Lifescience |
EV/EBITDA | 10.25 | 20.69 | Dishman Carbogen |
Profit Margin (TTM) | 3.60% | 26.16% | Supriya Lifescience |
Operating Margin (TTM) | 8.38% | 31.19% | Supriya Lifescience |
EBITDA Margin (TTM) | 8.38% | 31.19% | Supriya Lifescience |
Return on Equity | 0.06% | 18.86% | Supriya Lifescience |
Return on Assets (TTM) | 0.03% | 16.90% | Supriya Lifescience |
Free Cash Flow (TTM) | $1.58B | $22.99M | Dishman Carbogen |
Dividend Yield | N/A | 0.12% | N/A |
1-Year Return | 40.78% | 22.40% | Dishman Carbogen |
Price-to-Sales Ratio (TTM) | 1.43 | 7.69 | Dishman Carbogen |
Enterprise Value | $60.61B | $51.62B | Dishman Carbogen |
EV/Revenue Ratio | 2.09 | 7.58 | Dishman Carbogen |
Gross Profit Margin (TTM) | 79.63% | 78.10% | Dishman Carbogen |
Revenue per Share (TTM) | $188 | $85 | Dishman Carbogen |
Earnings per Share (Diluted) | $0.21 | $22.11 | Supriya Lifescience |
Beta (Stock Volatility) | 0.17 | 0.19 | Dishman Carbogen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dishman Carbogen vs Supriya Lifescience Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Dishman Carbogen | 0.93% | 10.98% | 4.89% | 24.38% | 20.94% | -5.56% |
Supriya Lifescience | 0.61% | 3.79% | -3.22% | -3.71% | 6.44% | -10.69% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Dishman Carbogen | 40.78% | 126.05% | 45.30% | 156.69% | 171.49% | 268.10% |
Supriya Lifescience | 22.40% | 85.62% | 40.01% | 40.01% | 40.01% | 40.01% |
Performance & Financial Health Analysis: Dishman Carbogen vs Supriya Lifescience
Metric | DCAL | SUPRIYA |
---|---|---|
Market Information | ||
Market Cap | ₹41.28B | ₹52.33B |
Market Cap Category | Small cap | Mid cap |
10 Day Avg. Volume | 116,293 | 190,623 |
90 Day Avg. Volume | 100,094 | 217,049 |
Last Close | ₹271.95 | ₹681.40 |
52 Week Range | ₹161.21 - ₹307.98 | ₹511.40 - ₹842.00 |
% from 52W High | -11.70% | -19.07% |
All-Time High | ₹396.40 (Jan 22, 2018) | ₹842.00 (Mar 31, 2025) |
% from All-Time High | -31.40% | -19.07% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.35% | -0.10% |
Quarterly Earnings Growth | 0.23% | -0.22% |
Financial Health | ||
Profit Margin (TTM) | 0.04% | 0.26% |
Operating Margin (TTM) | 0.08% | 0.31% |
Return on Equity (TTM) | 0.00% | 0.19% |
Debt to Equity (MRQ) | 40.97 | 0.54 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹372.17 | ₹124.44 |
Cash per Share (MRQ) | ₹33.89 | ₹9.83 |
Operating Cash Flow (TTM) | ₹-187,700,000 | ₹1.87B |
Levered Free Cash Flow (TTM) | ₹32.40M | ₹1.88B |
Dividends | ||
Last 12-Month Dividend Yield | N/A | 0.12% |
Last 12-Month Dividend | ₹0.00 | ₹0.80 |
Valuation & Enterprise Metrics Analysis: Dishman Carbogen vs Supriya Lifescience
Metric | DCAL | SUPRIYA |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 1,253.10 | 29.41 |
Forward P/E | 21.05 | 21.62 |
PEG Ratio | 21.05 | -1.34 |
Price to Sales (TTM) | 1.43 | 7.69 |
Price to Book (MRQ) | 0.71 | 5.22 |
Market Capitalization | ||
Market Capitalization | ₹41.28B | ₹52.33B |
Enterprise Value | ₹60.61B | ₹51.62B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 2.09 | 7.58 |
Enterprise to EBITDA | 10.25 | 20.69 |
Risk & Other Metrics | ||
Beta | 0.17 | 0.19 |
Book Value per Share (MRQ) | ₹372.17 | ₹124.44 |
Financial Statements Comparison: Dishman Carbogen vs Supriya Lifescience
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | DCAL | SUPRIYA |
---|---|---|
Revenue/Sales | ₹7.16B | ₹1.84B |
Cost of Goods Sold | ₹1.46B | ₹548.26M |
Gross Profit | ₹5.70B | ₹1.29B |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹736.00M | ₹615.04M |
EBITDA | ₹1.61B | ₹705.39M |
Pre-Tax Income | ₹277.00M | ₹640.60M |
Income Tax | ₹-153.90M | ₹136.80M |
Net Income (Profit) | ₹430.90M | ₹503.82M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | DCAL | SUPRIYA |
---|---|---|
Cash & Equivalents | ₹3.41B | ₹760.57M |
Total Current Assets | ₹22.00B | ₹4.37B |
Total Current Liabilities | ₹19.25B | ₹821.62M |
Long-Term Debt | ₹13.90B | ₹50.57M |
Total Shareholders Equity | ₹58.32B | ₹9.97B |
Retained Earnings | N/A | N/A |
Property, Plant & Equipment | ₹29.19B | ₹4.51B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | DCAL | SUPRIYA |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | DCAL | SUPRIYA |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 116,293 | 190,623 |
Average Daily Volume (90 Day) | 100,094 | 217,049 |
Shares Outstanding | 156.78M | 80.48M |
Float Shares | 55.23M | 25.53M |
% Held by Insiders | 0.71% | 0.72% |
% Held by Institutions | 0.02% | 0.05% |
Dividend Analysis & Yield Comparison: Dishman Carbogen vs Supriya Lifescience
Metric | DCAL | SUPRIYA |
---|---|---|
Last 12-Month Dividend | ₹0.00 | ₹0.80 |
Last 12-Month Dividend Yield | N/A | 0.12% |
3-Year Avg Annual Dividend | ₹0.00 | ₹0.67 |
3-Year Avg Dividend Yield | N/A | 0.18% |
3-Year Total Dividends | ₹0.00 | ₹2.00 |
Ex-Dividend Date | N/A | Sep 20, 2024 |